Oncology

Mapping cancer cells to genes helps to formulate a treatment plan.

One-fourth of standard dose with low-fat meal as effective as standard dose.

Marc O'Connor, COO and chief strategy officer at Curant Health, discusses how the shift to Medicare Part D could impact patients undergoing treatment for cancer.

Lynparza (olaparib) shows efficacy in a phase 3 clinical trial of BRCA-mutated HER2-negative metastatic breast cancer.

The phase 3 OLYMPIAD clinical trial met its primary endpoint of progression-free survival in breast cancer.

New technology can predict which patients will achieve remission and which will relapse.

Young children had more than twice the risk for overdose compared to children whose mothers were prescribed nonsteroidal anti-inflammatory drugs (NSAIDs) rather than opioids.

Top news of the week in oncology and cancer drug development.

The Akt protein is crucial for T cells to transform into memory T cells.

SF2523 can dually inhibit a protein and an enzyme associated with cancer.

Cancer cells adjusted to have normal circadian rhythm slowed tumor growth.

Tumor growth can be fueled by sleep disruption.

The Iowa Department of Public Health released its first report on hepatitis C virus.

Extrachromosomal oncogene helps drive tumor evolution and heterogeneity.

Lenalidomide (Revlimid) maintenance improved survival in multiple myeloma patients following a stem cell transplant.

Tumors containing JAK1 and JAK2 mutations effect response to immunotherapy in patients with melanoma and colon cancer.

Application filed for ceritinib (Zykadia) as a first-line treatment for patients with metastatic non-small cell lung cancer.

Top news of the day from across the health care landscape.

Zykadia granted breakthrough therapy designation for ALK+ metastatic non-small cell lung cancer with brain metastases.

The FDA has accepted Novartis’ supplemental new drug application (sNDA) for filing and granted priority review for the expanded use of a new cancer drug.

Physical activity drops during and after cancer treatment.

Consumption of beta-cryptoxanthin reduced lung cancer risk up to 63%.

SMAC mimetics and immune checkpoint inhibitors, together, promote tumor immunity against deadly brain cancer.

Top news of the week in oncology and cancer drug development.

Smokers who receive telephone-based smoking cessation counseling shortly after undergoing lung cancer screening may be more likely to quit smoking, a new Georgetown Lombardi-led study finds.

Targeted therapy improves survival rates for dogs with hemangiosarcoma.

Community Oncology Alliance at odds with the opinion of pharmacy benefit managers regarding direct and indirect remuneration fees.

The World Health Organization seeks to improve early cancer detection to increase survivors and cut treatment costs.

Aggressive cancers found more susceptible to combination treatment compared with monotherapy.

Stakeholders debate the benefits of direct and indirect remuneration fees.